Global biopharmaceutical corporation UCB is set to make a series of presentations at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin between June 6th and the 9th.
It is not the only firm to be doing so, as Bristol-Myers Squibb recently announced it will be detailing some of its clinical research findings into Orencia - a lyophilized powder for intravenous infusion that can be used as an alternative to an under-the-skin injection.
Professor Dr Iris Loew-Friedrich, chief medical officer and executive vice-president at UCB, stated that he is proud on behalf of his organisation to be able to demonstrate a commitment to improving the lifestyles of those with autoimmune diseases.
"The breadth of presentations in rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus and osteoporosis illustrate UCB's ongoing research in these areas," the expert commented.
These will be the four key disease areas that UCB will be focusing on at the EULAR conference.